Title : Long-term follow-up after gene therapy for canavan disease.

Pub. Date : 2012 Dec 19

PMID : 23253610






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Canavan disease is a hereditary leukodystrophy caused by mutations in the aspartoacylase gene (ASPA), leading to loss of enzyme activity and increased concentrations of the substrate N-acetyl-aspartate (NAA) in the brain. N-acetylaspartate aspartoacylase Homo sapiens
2 Canavan disease is a hereditary leukodystrophy caused by mutations in the aspartoacylase gene (ASPA), leading to loss of enzyme activity and increased concentrations of the substrate N-acetyl-aspartate (NAA) in the brain. N-acetylaspartate aspartoacylase Homo sapiens
3 AAV2-ASPA gene therapy resulted in a decrease in elevated NAA in the brain and slowed progression of brain atrophy, with some improvement in seizure frequency and with stabilization of overall clinical status. N-acetylaspartate aspartoacylase Homo sapiens